Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP8374 and Cemiplimab in Recurrent Malignant Glioma
NCT04826393Phase 1Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Mar 2022
- Primary completion
- Oct 2022
- Modality
- Prophylactic Vaccines, IgG Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ASP8374 in glioblastoma (GBM) (3 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Maximum Tolerated Dose / Recommended Phase 2 Dose up to 2 years and CD8+ Tumor Infiltrating Lymphocyte Density up to 2 years. Started Mar 2022; status: completed.
02
Drugs
ASP8374
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04826393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04826393.